Eptifibatide infusion versus placebo in high risk patients with non-st segment elevation acute coronary syndromes managed with urgent coronary artery bypass graft surgery. a prospective multicenter randomized placebo-controlled clinical trial.

CONCLUSION: Preoperative use of eptifibatide vs. placebo is linked to significantly reduced 12--month MACCE rate in patients with NSTE--ACS requiring urgent CABG, while it simultaneously seems not to confer a greater risk of postoperative bleeding. PMID: 25394877 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/25394877?dopt=Abstract

Source: The Journal of Cardiovascular Surgery - November 14, 2014 Category: Cardiovascular & Thoracic Surgery Authors: Wilczynski M, Wybraniec MT, Milewski K, Sanak M, Wita K, Buldak L, Kondys M, Buszman P, Bochenek A Tags: J Cardiovasc Surg (Torino) Source Type: research